PLoS ONE · 2008 · 287 citations · 48 references
CAF01 is potentially a suitable adjuvant for a wide range of diseases including targets requiring both CMI and humoral immune responses for protection.
48
Armelle Régnault, Danielle Lankar, Valérie Lacabanne et al. · The Journal of Experimental Medicine · 1999 · 879 citations · Full text
FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Falk Nimmerjahn, Pierre Bruhns, Ken Horiuchi et al. · Immunity · 2005 · 648 citations · Full text
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
Amanda L. Gavin, Kasper Hoebe, Bao Duong et al. · Science · 2006 · 569 citations · Full text